High Time for High-Dose Flu Vaccines in Cardiovascular Patients?

Bahar Behrouzi^{1

2

3}, Jacob A Udell^{1

2

4

3

5}

Affiliations

¹ Institute of Health Policy, Management and Evaluation (B.B., J.A.U.), University of Toronto, Ontario, Canada.
² Temerty Faculty of Medicine (B.B., J.A.U.), University of Toronto, Ontario, Canada.
³ Cardiovascular Division, Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada (B.B., J.A.U.).
⁴ Department of Medicine (J.A.U.), University of Toronto, Ontario, Canada.
⁵ Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada (J.A.U.).

PMID: 39965043
DOI: 10.1161/CIRCOUTCOMES.124.011857

Editorial

High Time for High-Dose Flu Vaccines in Cardiovascular Patients?

Bahar Behrouzi et al. Circ Cardiovasc Qual Outcomes. 2025 Feb.

. 2025 Feb;18(2):e011857.

doi: 10.1161/CIRCOUTCOMES.124.011857. Epub 2025 Feb 18.

Authors

Bahar Behrouzi^{1

2

3}, Jacob A Udell^{1

2

4

3

5}

Affiliations

¹ Institute of Health Policy, Management and Evaluation (B.B., J.A.U.), University of Toronto, Ontario, Canada.
² Temerty Faculty of Medicine (B.B., J.A.U.), University of Toronto, Ontario, Canada.
³ Cardiovascular Division, Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada (B.B., J.A.U.).
⁴ Department of Medicine (J.A.U.), University of Toronto, Ontario, Canada.
⁵ Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada (J.A.U.).

PMID: 39965043
DOI: 10.1161/CIRCOUTCOMES.124.011857

No abstract available

Keywords: Editorials; atrial fibrillation; heart failure; incidence; seasons.

PubMed Disclaimer

Conflict of interest statement

Dr Behrouzi has received research grant support to her institutions from Boehringer Ingelheim, Lilly, and Sanofi-Aventis, unrelated to this work. Dr Udell has served as a consultant or speaker for AstraZeneca, Bayer, Boehringer Ingelheim-Lilly, Janssen, Novavax, Novartis, and Sanofi and has received research grants from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim-Lilly, and Janssen.

Comment on

Relative Effectiveness of High-Dose Versus Standard-Dose Quadrivalent Influenza Vaccine in Older Adults With Cardiovascular Disease: A Prespecified Analysis of the DANFLU-1 Randomized Clinical Trial.
Christensen J, Johansen ND, Modin D, Janstrup KH, Nealon J, Samson S, Loiacono M, Harris R, Larsen CS, Jensen AMR, Landler NE, Claggett BL, Solomon SD, Gislason GH, Køber L, Landray MJ, Sivapalan P, Jensen JUS, Biering-Sørensen T. Christensen J, et al. Circ Cardiovasc Qual Outcomes. 2025 Feb;18(2):e011496. doi: 10.1161/CIRCOUTCOMES.124.011496. Epub 2024 Aug 31. Circ Cardiovasc Qual Outcomes. 2025. PMID: 39215646 Clinical Trial.

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

High Time for High-Dose Flu Vaccines in Cardiovascular Patients?

Affiliations

High Time for High-Dose Flu Vaccines in Cardiovascular Patients?

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

LinkOut - more resources

Full Text Sources